GYRE THERAPEUTICS, INC. — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Gyre Therapeutics formalized employment agreements with Ying Luo (CEO, $500k base + $150k target bonus) and Thomas Eastling (CFO, $339.1k base + $70k target bonus), both dated October 16, 2026. Agreements include severance of 6 months base salary outside change-of-control periods, and 1× base plus target bonus in lump sum during change-of-control windows, plus accelerated equity vesting and COBRA coverage. Both supersede prior arrangements including with Cullgen Inc.
Why this rating
Routine executive employment formalization. Combined ~$1.06M annual comp is ~1.5% of $72.6M market cap; severance exposure modest. No material new terms or unusual provisions; standard governance document.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.